Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2
NCT ID: NCT04222985
Last Updated: 2022-10-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
24 participants
INTERVENTIONAL
2020-02-18
2021-05-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* To describe the safety profile of different investigational vaccine regimens against herpes simplex virus type 2 (HSV-2).
* To evaluate the efficacy of the investigational vaccine regimens with respect to:
* the frequency of herpes simplex virus (HSV) deoxyribonucleic acid (DNA) detection in the genital area (shedding rate) following a 2 dose vaccine schedule
* the proportion of participants free of HSV genital recurrence at 6 months after the 2-dose vaccine schedule
The secondary objectives of the study are:
* To describe the impact of each of the investigational vaccine regimens in terms of total number of days with genital lesion up to 6 months after vaccination 2 and number of recurrences 60 days after the second vaccination compared with the placebo group
* To describe the efficacy of each of the investigational vaccine regimens with respect to the frequency of HSV DNA detection in the genital area (shedding rate) 60 days following the first vaccination visit plus 60 days following the second vaccination visit compared with the placebo group
* To describe the efficacy of each of the investigational vaccine regimens with respect to the frequency of HSV DNA detection in the genital area (shedding rate) 60 days following the first vaccination visit compared with the placebo group
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years
NCT04762511
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
NCT02837575
Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection
NCT01915212
Safety Study of HSV2 DNA Vaccine to Treat Patients With Recurrent Genital Herpes Caused by HSV-2
NCT00274300
Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults
NCT02030301
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part A - Group 1
HSV 2 formulation 1 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
HSV 2 Formulation 1
Route of administration: Intramuscular
Sodium Chloride 0.9%
Route of administration: Intramuscular
Part A - Group 2
HSV 2 formulation 2 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
HSV 2 Formulation 2
Route of administration: Intramuscular
Sodium Chloride 0.9%
Route of administration: Intramuscular
Part A - Group 3
HSV 2 Formulation 3 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
HSV 2 Formulation 3
Route of administration: Intramuscular
Sodium Chloride 0.9%
Route of administration: Intramuscular
Part A - Group 4
HSV 2 Formulation 4 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0, then HSV 2 Formulation 3 administered with concomitantly with 0.9% sodium chloride in the opposite arm at Month 2
HSV 2 Formulation 3
Route of administration: Intramuscular
HSV 2 Formulation 4
Route of administration: Intramuscular
Sodium Chloride 0.9%
Route of administration: Intramuscular
Part A - Group 5
HSV 2 Formulation 5 administered in one arm and Formulation 3 in the opposite arm, at Month 0 and Month 2.
HSV 2 Formulation 3
Route of administration: Intramuscular
HSV 2 Formulation 5
Route of administration: Intramuscular
Part A - Group 6
Sodium chloride 0.9% (in both arms) at Month 0 and Month 2
Sodium Chloride 0.9%
Route of administration: Intramuscular
Part B (Stage 1) - Group 1
HSV 2 Formulation 1 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
HSV 2 Formulation 1
Route of administration: Intramuscular
Sodium Chloride 0.9%
Route of administration: Intramuscular
Part B (Stage 1) - Group 2
HSV 2 Formulation 2 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
HSV 2 Formulation 2
Route of administration: Intramuscular
Sodium Chloride 0.9%
Route of administration: Intramuscular
Part B (Stage 1) - Group 3
HSV 2 Formulation 3 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
HSV 2 Formulation 3
Route of administration: Intramuscular
Sodium Chloride 0.9%
Route of administration: Intramuscular
Part B (Stage 1) - Group 4
HSV 2 Formulation 4 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0, then HSV 2 Formulation 3 administered with concomitantly with 0.9% sodium chloride in the opposite arm at Month 2
HSV 2 Formulation 3
Route of administration: Intramuscular
HSV 2 Formulation 4
Route of administration: Intramuscular
Sodium Chloride 0.9%
Route of administration: Intramuscular
Part B (Stage 1) - Group 5
HSV 2 Formulation 5 administered in one arm and Formulation 3 in the opposite arm, at Month 0 and Month 2
HSV 2 Formulation 3
Route of administration: Intramuscular
HSV 2 Formulation 5
Route of administration: Intramuscular
Part B (Stage 1) - Group 6
Sodium Chloride 0.9% (in both arms) at Month 0 and Month 2
Sodium Chloride 0.9%
Route of administration: Intramuscular
Part B (Stage 1) - Group 7
HSV 2 Formulation 6 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
HSV 2 Formulation 6
Route of administration: Intramuscular
Sodium Chloride 0.9%
Route of administration: Intramuscular
Part B (Stage 2) - Group 1
HSV 2 Formulation 1 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
HSV 2 Formulation 1
Route of administration: Intramuscular
Sodium Chloride 0.9%
Route of administration: Intramuscular
Part B (Stage 2) - Group 2
HSV 2 Formulation 2 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
HSV 2 Formulation 2
Route of administration: Intramuscular
Sodium Chloride 0.9%
Route of administration: Intramuscular
Part B (Stage 2) - Group 3
HSV 2 Formulation 3 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
HSV 2 Formulation 3
Route of administration: Intramuscular
Sodium Chloride 0.9%
Route of administration: Intramuscular
Part B (Stage 2) - Group 4
HSV 2 Formulation 4 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0, then HSV 2 Formulation 3 administered with concomitantly with 0.9% sodium chloride in the opposite arm at Month 2
HSV 2 Formulation 3
Route of administration: Intramuscular
HSV 2 Formulation 4
Route of administration: Intramuscular
Sodium Chloride 0.9%
Route of administration: Intramuscular
Part B (Stage 2) - Group 5
HSV 2 Formulation 5 administered in one arm and Formulation 3 in the opposite arm, at Month 0 and Month 2
HSV 2 Formulation 3
Route of administration: Intramuscular
HSV 2 Formulation 5
Route of administration: Intramuscular
Part B (Stage 2) - Group 6
Sodium Chloride 0.9% (in both arms) at Month 0 and Month 2
Sodium Chloride 0.9%
Route of administration: Intramuscular
Part B (Stage 2) - Group 7
HSV 2 Formulation 6 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
HSV 2 Formulation 6
Route of administration: Intramuscular
Sodium Chloride 0.9%
Route of administration: Intramuscular
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HSV 2 Formulation 1
Route of administration: Intramuscular
HSV 2 Formulation 2
Route of administration: Intramuscular
HSV 2 Formulation 3
Route of administration: Intramuscular
HSV 2 Formulation 4
Route of administration: Intramuscular
HSV 2 Formulation 5
Route of administration: Intramuscular
HSV 2 Formulation 6
Route of administration: Intramuscular
Sodium Chloride 0.9%
Route of administration: Intramuscular
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Informed consent form has been signed and dated
* Able to attend all scheduled visits and to comply with all trial procedures
* In good general health with absence of significant health problems as determined by medical history, physical examination, and laboratory screening performed during screening visits
* HSV-2 seropositive confirmed by Western blot
* A history of established HSV-2 infection ≥ 1 year
* A history of at least 2 and no more than 9 reported HSV clinical recurrences in the prior 12 months, or, if currently on suppressive therapy, history of at least 2 and no more than 9 reported clinical recurrences in the 12 months prior to initiation suppressive therapy
* For Part A and Part B, the participant is willing to refrain from using suppressive antiviral therapy starting 5 days before the first vaccination visit and up to 6 months after the second vaccination visit; and for Part B, throughout the 3, 60-day swabbing periods, and up to 6 months after the second vaccination visit
* For Part A and Part B, the participant is willing to refrain from using antiviral therapy to treat recurrences starting 5 days before V01 and up to 6 months after the second vaccination visit; and for Part B, throughout the 3, 60-day swabbing periods (i.e., up to 60 days after the second vaccination visit)
Exclusion Criteria
* For Part B, the participant is pregnant, or lactating, or of childbearing potential and not using an effective method of contraception or abstinence with her/his partner from at least 4 weeks before the enrollment visit until at least 6 months after the last vaccination. To be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year, or surgically sterile.
* Participants whose female partners are pregnant at the time of enrollment or plan to become pregnant between study entry through 12 weeks (for Part A) and 6 months (for Part B) after the second vaccination visit.
* Participation at the time of study enrollment (or in the 4 weeks preceding the first trial vaccination) or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure
* Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
* Receipt of any vaccine in the 4 weeks preceding the first study vaccination or planned receipt of any vaccine in the 4 weeks before and/or following any trial vaccination except for influenza vaccination, which may be received at a gap of at least 2 weeks before or 2 weeks after any study vaccination
* Current alcohol abuse or drug addiction
* Positive serologic test or polymerase chain reaction for human immunodeficiency virus type 1 infection
* Positive hepatitis B surface antigen
* Positive antibody for hepatitis C virusribonucleic acid and positive hepatitis C test
* Severe active infection or serious HSV-2 related medical conditions on the day of enrollment that, in the opinion of the Investigator, would prevent study completion
* Active genital herpes determined by the presence of outbreaks (genital lesions) at the time of enrollment. A prospective subject should not be included in the trial until 24 hours after the outbreak has resolved (the lesions have completely disappeared)
* Hemoglobin, white blood cell count with differential, platelet count, renal function tests (serum creatinine, blood urea nitrogen), liver function tests, creatine phosphokinase and C-reactive protein screening laboratory results that fall into the range of values that are Grade 2 or greater as per the study toxicity grading scale for this study. Also the range of values that are Grade 1 and are deemed clinically significant in the opinion of the Investigator (Grade 1 values deemed not clinically significant may be enrolled at the Investigator's discretion)
* Previous vaccination against HSV infection with either the trial vaccine or another vaccine against HSV
* History of HSV infection of the eye (e.g., herpes simplex interstitial keratitis or uveitis)
* History of eczema herpeticum
* History of herpes-associated erythema multiforme
* History of lesions caused by HSV on either arm
* History of any autoimmune disorder
* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
* Receipt of immune globulins, blood or blood-derived products in the past 3 months
* Thrombocytopenia or bleeding disorder, contraindicating IM vaccination based on Investigator's judgment
* Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances
* Known allergy or intolerance to nickel
* Known allergy or intolerance to acyclovir or valacyclovir
* Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study
* Chronic illness or other conditions that, in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion
* Moderate or severe acute illness/infection (according to the Investigator's judgment) on the day of vaccination or febrile illness (temperature ≥ 100.4 °F (\[≥ 38 °C\]).
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
INDUSTRY
Sanofi Pasteur, a Sanofi Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Sciences & Operations
Role: STUDY_DIRECTOR
Sanofi Pasteur, a Sanofi Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Centers of America-Site Number:8400010
Hollywood, Florida, United States
Brigham and Womens Hospital-Site Number:8400003
Boston, Massachusetts, United States
M3 Wake Research Inc-Site Number:8400006
Raleigh, North Carolina, United States
University of Washington Virology Research Clinic-Site Number:8400001
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1183-6522
Identifier Type: OTHER
Identifier Source: secondary_id
HSV15
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.